Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$3.8 million.

  • Serina Therapeutics' Free Cash Flow fell 2934.23% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.6 million, marking a year-over-year decrease of 3245.17%. This contributed to the annual value of -$17.2 million for FY2024, which is 47580.54% down from last year.
  • As of Q3 2025, Serina Therapeutics' Free Cash Flow stood at -$3.8 million, which was down 2934.23% from -$3.8 million recorded in Q2 2025.
  • Serina Therapeutics' 5-year Free Cash Flow high stood at $51000.0 for Q4 2023, and its period low was -$8.0 million during Q2 2024.
  • For the 5-year period, Serina Therapeutics' Free Cash Flow averaged around -$2.4 million, with its median value being -$1.7 million (2021).
  • Per our database at Business Quant, Serina Therapeutics' Free Cash Flow skyrocketed by 10386.07% in 2023 and then crashed by 910784.31% in 2024.
  • Over the past 5 years, Serina Therapeutics' Free Cash Flow (Quarter) stood at -$1.6 million in 2021, then increased by 19.79% to -$1.3 million in 2022, then skyrocketed by 103.86% to $51000.0 in 2023, then tumbled by 9107.84% to -$4.6 million in 2024, then increased by 16.52% to -$3.8 million in 2025.
  • Its Free Cash Flow stands at -$3.8 million for Q3 2025, versus -$3.8 million for Q2 2025 and -$4.3 million for Q1 2025.